Wealthspire Advisors (New York)’s GSK GSK Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$651K	Buy	12,426 +3,843	+45%	+$203K	﹤0.01%	698
2026 Q1	$474K	Buy	8,583 +1,236	+17%	+$67K	﹤0.01%	586
2025 Q4	$360K	Buy	7,347 +4,751	+183%	+$222K	﹤0.01%	726
2025 Q3	$112K	Buy	+2,596	New	+$101K	﹤0.01%	978
2022 Q1	–	Sell	-3,716	Closed	-$205K	–	485
2021 Q4	$205K	Sell	3,716 -980	-21%	-$51K	﹤0.01%	516
2021 Q3	$224K	Buy	+4,696	New	+$236K	﹤0.01%	522
2020 Q2	–	Sell	-6,690	Closed	-$317K	–	374
2020 Q1	$317K	Buy	+6,690	New	+$357K	0.01%	371
2019 Q1	–	Sell	-978	Closed	-$47K	–	352
2018 Q4	$47K	Buy	+978	New	+$48.2K	﹤0.01%	192

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wealthspire Advisors (New York)'s GSK Position: Q2 2026 in Review

Wealthspire Advisors (New York) increased its GSK (GSK) stake by 45% in Q2 2026, buying an estimated $203K and bringing the position to 12,426 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Wealthspire Advisors (New York) first reported a position in GSK in Q4 2018 and has held it in 8 quarters since. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Wealthspire Advisors (New York) held 12,426 shares of GSK worth $651K as of Q2 2026.
Wealthspire Advisors (New York) bought 3,843 GSK shares in Q2 2026, an estimated $203K.
GSK made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #698 holding.
Wealthspire Advisors (New York) first reported a position in GSK in Q4 2018 and has held it in 8 quarters since.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.